Samsung Biologics Co., a biotech arm of South Korea's Samsung Group, said Thursday it plans to spin off its biosimilar ...

Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global ...

South Korean Samsung Group’s biopharmaceutical business is being reorganized into two separate tracks: contract development ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

President Donald Trump put the biopharma industry on its back foot earlier this month with his executive order on ...

FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone ...

Fresenius Kabi Canada announces that its tocilizumab biosimilar Tyenne® referencing Actemra®** (tocilizumab) is now commercially available in Canada. Tyenne® is the first and only tocilizumab ...

Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, announced Thursday that it plans to spin off its ...

Samsung Biologics Co., a biotech arm of South Korea's Samsung Group, said Thursday it plans to spin off its biosimilar ...